Abstract
Thioether lysophospholipid derivatives (TLP) inhibited the in vitro uptake of [3H]thymidine into blasts of eight leukemias and cells of 12 different solid tumors of human origin. This effect correlated with trypan blue dye exclusion, which was used to assess cell damage.
Cytostatic and cytotoxic effects of TLP were dependent on dosage and incubation time. Destruction of leukemic blasts was completed with >5 μg/ml after an incubation of >48 hr, but 10 to 20 μg/ml were necessary in solid tumors. Ester-linked 2-lysophosphatidylcholine was ineffective in the same dose range, which points to the requirement of the alkyl moiety insn-1 and a stablesn-2 substitution of the molecule for the antineoplastic effect.
To assess putative antileukemic selectivity, the cytotoxicity (trypan blue dye exclusion) of TLP was compared in human cell samples of 19 non-neoplastic bone marrows and 9 leukemias. Results revealed a significantly higher activity of the TLP BM 41.440 in leukemic blasts.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- TLP:
-
thioether lysophospholipid derivative(s)
- ALP:
-
alkyl lysophospholipid derivative(s)
- 2-LPC:
-
2-lysophosphatidyl-choline
- AL:
-
acute leukemia(s)
- CML/BC:
-
blast crisis of chronic myelogenous leukemia
References
Robertson, A.F., and Lands, W.E.M. (1964)J. Lipid Res. 5, 88–93.
Andreesen, R., Modelell, M., Weltzien, H.U., Eibl, H., Common, H.H., Loehr, G.W., and Munder, P.G. (1978)Cancer Res. 38, 3894–3899.
Tidwell, T., Guzman, G., and Vogler, W.R. (1981)Blood 57, 794–797.
Berdel, W.E., Fink, U., Egger, B., Reichert, A., Munder, P.G., and Rastetter, J. (1981)J. Natl. Cancer Inst. 66, 813–817.
Runge, M.H., Andreesen, R., Pfleiderer, A., and Munder, P.G. (1980)J. Natl. Cancer Inst. 64, 1301–1306.
Munder, P.G., Modolell, M., Bausert, W., Oettgen, H.F., and Westphal, O. (1981) inAugmenting Agents, in Cancer Therapy (Hersh, E.M., et al., eds.) pp. 441–458, Raven Press, New York.
Munder, P.G., Weltzien, H.U., and Modolell, M. (1977) inVII International Symposium of Immunopathology, Bad Schachen, Germany (Miescher, P.A., ed.) pp. 411–424, Schwabe & Co., Basel, Switzerland.
Berdel, W.E., Bausert, W.R., Weltzien, H.U., Modolell, M.L., Widmann, K.H., and Munder, P.G. (1980)Eur. J. Cancer 16, 1199–1204.
Berger, M.R., Munder, P.G., Schmähl, D., and Westphal, O. (1984)Oncology 41, 109–113.
Modolell, M., Andreesen, R., Pahlke, W., Brugger, U., and Munder, P.G. (1979)Cancer Res. 39, 4681–4686.
Helfman, D.M., Barnes, K.C., Kinkade, J.M. Jr., Vogler, W.R., Shoji, M., and Kuo, J.F. (1983)Cancer Res. 43, 2955–2961.
Honma, Y., Kasukabe, T., Hozumi, M., Tsushima, S., and Nomura, H. (1981)Cancer Res. 41, 3211–3216.
Storme, G.A., Berdel, W.E., van Blitterswijk, W.J., Bruyneel, E.A., De Bruyne, G.K., and Mareel, M.M. (1985)Cancer Res. 45, 351–357.
Berdel, W.E., Fronm, M., Fink, U., Pahlke, W., Bicker, U., Reichert, A., and Rastetter, J. (1983)Cancer Res. 43, 5538–5543.
Berdel, W.E., Schick, H.D., Fink, U., Reichert, A., Ulm, K., and Rastetter, J. (1985)Cancer Res. 45, 1206–1213.
Herrmann, D.B.J., Neumann, H.A., Berdel, W.E., Heim, M.E., Fromm, M., Boerner, D., and Bicker, U. (1987)Lipid 22, 962–966.
Author information
Authors and Affiliations
About this article
Cite this article
Fromm, M., Berdel, W.E., Schick, H.D. et al. Antineoplastic activity of the thioether lysophospholipid derivative BM 41.440 in vitro. Lipids 22, 916–918 (1987). https://doi.org/10.1007/BF02535554
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02535554